INSY - インシス・セラピュ―ティクス (Insys Therapeutics Inc.) インシス・セラピュ―ティクス

 INSYのチャート


 INSYの企業情報

symbol INSY
会社名 Insys Therapeutics Inc (インシス・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 インシス・セラピューティックス(Insys Therapeutics Inc.)は商業段階の専門製薬企業。同社は支持療法の製品開発と商業化を行う。同社の製品Subsysはオピオイド耐性患者の突出がん疼痛(BTCP)治療用の舌下フェンタニルスプレーおよび舌下の経粘膜吸収用のオピオイド鎮痛薬フェンタニルを与える単回使用製品である。同社のSubsys販売活動はアメリカの支持療法医師に集中して展開して、約100、200、400、600、800、1200および1600マイクログラム(mcg)の投薬量で液体フェンタニル製剤を提供する。同社のリードドロナビノール製品候補はSyndrosである。Syndrosはアメリカ食品医薬品局(Food and Drug Administration; FDA)承認審査中である。同社は前臨床試験でドロナビノールの舌下噴霧、吸入および静脈内製剤を評価する。   インシス・セラピュ―ティクスは、商用段階の米国の医薬品会社。支持療法製品を開発し、商業化する。製品は、オピオイド耐性患者における癌性疼痛のための舌下フェンタニルスプレ―の「SUBSYS」、マリノ―ル(ドロナビノ―ル)のジェネリック医薬品などの「ドロナビノ―ルSGカプセル」がある。   INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ.
本社所在地 1333 S. Spectrum Blvd. Suite 100 Chandler AZ 85286 USA
代表者氏名 Steven J. Meyer スティーブンJ.マイヤー
代表者役職名 Independent Chairman of the Board
電話番号 +1 602-910-2617
設立年月日 33025
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 343人
url www.insysrx.com
nasdaq_url https://www.nasdaq.com/symbol/insy
adr_tso
EBITDA EBITDA(百万ドル) -80.96800
終値(lastsale) 8.85
時価総額(marketcap) 657067134.9
時価総額 時価総額(百万ドル) 661.52190
売上高 売上高(百万ドル) 109.53200
企業価値(EV) 企業価値(EV)(百万ドル) 556.61890
当期純利益 当期純利益(百万ドル) -253.52700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Insys Therapeutics Inc revenues decreased 40% to $47.4M. Net loss increased from $14.7M to $47.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development - Other increase from $11.9M to $27.2M (expense) General and administrative - Other increase from $12.1M to $25.8M (expense).

 INSYのテクニカル分析


 INSYのニュース

   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Insys Down on Bankruptcy News Amid Increasing Legal Expenses  2019/06/11 22:16:00 Zacks Investment Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.
   Insys files for bankruptcy after settling opioid case  2019/06/10 14:41:01 New York Post
Drugmaker Insys Therapeutics filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a US probe into bribes it paid to doctors for prescribing a powerful opioid medication. The filing in US Bankruptcy Court in the District of Delaware made Insys the first drug manufacturer to…
   Opioid maker Insys Therapeutics files Chapter 11 bankruptcy after corruption charges  2019/06/10 13:20:19 USA Today
Pharmaceutical company Insys Therapeutics filed for Chapter 11 bankruptcy protection Monday less than a week after pleading guilty to fraud charges.
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Insys Down on Bankruptcy News Amid Increasing Legal Expenses  2019/06/11 22:16:00 Zacks Investment Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.
   Insys files for bankruptcy after settling opioid case  2019/06/10 14:41:01 New York Post
Drugmaker Insys Therapeutics filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a US probe into bribes it paid to doctors for prescribing a powerful opioid medication. The filing in US Bankruptcy Court in the District of Delaware made Insys the first drug manufacturer to…
   Opioid maker Insys Therapeutics files Chapter 11 bankruptcy after corruption charges  2019/06/10 13:20:19 USA Today
Pharmaceutical company Insys Therapeutics filed for Chapter 11 bankruptcy protection Monday less than a week after pleading guilty to fraud charges.
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Insys Down on Bankruptcy News Amid Increasing Legal Expenses  2019/06/11 22:16:00 Zacks Investment Research
Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.
   Insys files for bankruptcy after settling opioid case  2019/06/10 14:41:01 New York Post
Drugmaker Insys Therapeutics filed for Chapter 11 bankruptcy protection on Monday, about a week after agreeing to pay $225 million to settle a US probe into bribes it paid to doctors for prescribing a powerful opioid medication. The filing in US Bankruptcy Court in the District of Delaware made Insys the first drug manufacturer to…
   Opioid maker Insys Therapeutics files Chapter 11 bankruptcy after corruption charges  2019/06/10 13:20:19 USA Today
Pharmaceutical company Insys Therapeutics filed for Chapter 11 bankruptcy protection Monday less than a week after pleading guilty to fraud charges.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 インシス・セラピュ―ティクス INSY Insys Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)